Evolution-based mathematical models significantly prolong response to abiraterone in metastatic castrate-resistant prostate cancer and identify strategies to further improve outcomes

BACKGROUND: Abiraterone acetate is an effective treatment for metastatic castrate-resistant prostate cancer (mCRPC), but evolution of resistance inevitably leads to progression. We present a pilot study in which abiraterone dosing is guided by evolution-informed mathematical models to delay onset of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jingsong, Cunningham, Jessica, Brown, Joel, Gatenby, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2022
Materias:
Evolutionary Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239688/
https://www.ncbi.nlm.nih.gov/pubmed/35762577
http://dx.doi.org/10.7554/eLife.76284

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239688/
https://www.ncbi.nlm.nih.gov/pubmed/35762577
http://dx.doi.org/10.7554/eLife.76284

Ejemplares similares